Mind Body Balance for Pediatric Migraine

Inclusion Criteria:

• Diagnosis: Migraine with or without aura or chronic migraine that meets theInternational Classification of Headache Disorders(ICHD) criteria

• Frequency: Headache frequency based upon prospective headache diary of 28 days mustbe ≥ 4 and ≤ 28.

• PedMIDAS: PedMIDAS Disability Score > 4, indicating at least mild disruption indaily activities and < 140, indicating extreme disability that may require morecomprehensive, multi-component therapy

• Use of one or more of the following prescribed nutraceuticals and/or preventiveanti-migraine medications at the time or randomization or be on a stable dose of oneor more of the following throughout the 12 weeks of the study [Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol/Cholecalciferol), Depakote (Divalproate), Inderal (Propanerol),Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)]

• Language: English speaking, able to complete interviews and questionnaires inEnglish

Exclusion Criteria:

• Continuous migraine defined as unrelenting headache for a 28 day period

• Must agree not to take non-specific acute medication, such as NSAIDS (e.g.,ibuprofen), more than 3 times per week, or migraine specific acute medications, suchas triptans, more than 6 times per month (to prevent medication overuse headache)

• PedMIDAS Disability Score > 140, indicating extreme disability that may require morecomprehensive, multi-component therapy

• Youth who are pregnant, or those who are sexually active and not using a medicallyaccepted form of contraception (barrier or hormonal methods)

• Present severe psychiatric disease, alcohol or drug dependence, or documenteddevelopmental delays or impairments (e.g., autism, cerebral palsy, or mentalretardation) or other circumstances, that, in the opinion of the investigator, wouldinterfere with adherence to study requirements or safe participation in the study